Prostate Cancer Clinical Trial
Official title:
Multicentre Study Evaluating the Use of a Biodegradable Balloon for the Treatment of Prostate Cancer (of Intermediate Risk) by Intensity Modulated Conformal Radiotherapy (BioPro-RCMI)
The benefit of dose escalation in radiotherapy (RT) for biochemical control of prostate
cancer is a clearly established fact based on the results of different published prospective
trials. This benefit, acquired with three-dimensional conformal radiation technique is
counterbalanced by an increase in urinary and gastrointestinal toxicity. The joint progress
of dose planning systems and multileaf collimators (MLC) technology have enabled the
Intensity Modulated Radiation Therapy (IMRT). Recently the contribution of "spacers"
positioned in the septum between the rectum and the prostate could improve the functional
results of IMRT in terms of rectal toxicity.
The aim of the investigators study is to assess the dosimetric gain from the contribution of
the implantable BioProtect balloon on organs at risk.
Patients eligible for the trial and having signed their consent to participate will undergo a
scan to verify the possibility of implantation of the balloon. Before and after implantation
of the balloon, a dosimetric scan will be performed. Radiotherapy will be administered
according to the habits of each centre : Intensity modulated radiotherapy : 2 Gy / session, 5
weekly sessions, total dose of 74-80 Gy (+/- associated with an hormone therapy).
Patients will have a clinical examination :
- prior to the start of treatment
- once a week during the radiotherapy
- at the end of the radiotherapy
- and at the end of the study.
They will also complete quality of life questionnaires :
- prior to the start of treatment
- at mid-treatment
- at the end of the radiotherapy
- and at 3, 6, 12 and 24 months after the end of the radiotherapy.
Finally, patients will undergo a laboratory examination :
- prior to the start of treatment
- 3 months after the end of the radiotherapy
- and then every 6 months.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
| Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
| Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
| Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
| Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
| Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
| Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
| Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |